September 26, 2024 09:00 PM EDT
Startups
Special

End­points 11 win­ner As­cid­i­an Ther­a­peu­tics: A search-and-re­place tech­nol­o­gy comes to RNA

Ryan Cross

Senior Science Correspondent

↑
  • CEO Michael Ehlers
  • To­tal raised $90 mil­lion
  • Head­quar­ters Boston, MA

As­cid­i­an Ther­a­peu­tics has a se­cret list of near­ly 400 dis­eases …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Take­da to pay $200M for rights to ane­mia drug from Keros

Janux soars on ear­ly prostate can­cer da­ta that could chal­lenge No­var­tis' Plu­vic­to

Rev­o­lu­tion sells $600M in shares on back of RAS in­hibitor port­fo­lio up­dates

Roche teams up with Chica­go au­toim­mune biotech COUR Phar­ma­ceu­ti­cals

Gilead makes an­oth­er ADC move, ink­ing up to $415M pact with Tubu­lis

Ipsen se­cures rights to pre­clin­i­cal T cell en­gager in $610M pact with French biotech

A service from the Financial Times